Dishman Group, leading outsourcing partner for the global pharmaceutical industry, has announced the successful completion of an inspection by the U.S. Food and Drug Administration (FDA) for its site located in Veenendaal, The Netherlands.

The inspection, carried out by an USFDA investigator, was planned for 5 days but lasted 3 days, starting on January 24, 2015 and concluding on January 26, 2015. The inspection confirmed the site is compliant with the principles and guidelines of current Good Manufacturing Practices (cGMP).

"This success is the result of great team work. I would like to express my thanks to my staff. The entire team contributed to this successful inspection and I'm very proud of them," commented Mark Ipema, VP Operations, Dishman Netherlands. "The result we have achieved is of great importance not only to Dishman Netherlands, but also to the entire Dishman Group, demonstrating our commitment to meeting and exceeding customer requirements."

Dishman Netherlands, located in Veenendaal, is active in the marketing, sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, food, feed and industry applications. ISO 9001 and 14001 certified, the site is equipped of a full cGMP production laboratory.

"I'm very satisfied that our team at Dishman Netherlands have been able to demonstrate their compliance to the GMP's" said Mark Griffiths, Dishman CEO. "Quality is central to the Dishman business and we constantly strive to ensure that worker safety and product quality are never compromised. This is a great result, rewarding all efforts of Dishman Netherlands, but also other Dishman sites, to make sure quality and efficiently are our priority."